This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Laserscope (LSCP) were among the worst-performing health-related stocks Monday, slumping 13% after the medical device company's first-quarter results missed Wall Street's expectation.

The company earned $2.8 million, or 12 cents a share, on revenue of $32 million. The results included stock-based compensation costs of 2 cents a share. Analysts polled by Thomson First Call expected earnings of 17 cents a share and revenue of $34.9 million. During the year-earlier quarter, the company earned $5 million, or 22 cents a share, on revenue of $28.2 million.

Laserscope continues to project full-year earnings of 72 cents to 75 cents a share, excluding stock-based compensation costs. Analysts project earnings of 79 cents a share. Shares were trading down $3.05 to $20.71.

NeoPharm (NEOL) fell 6% after the biotechnology company said it slashed its workforce by 23%. The move, which was announced Friday evening, is designed to cut annual expenses by about $7 million. "The goal of this program is to balance and achieve efficiencies which adequately support the company's business strategy," the company said. About half of the savings will be realized during 2006, NeoPharm said. Shares were down 44 cents to $7.55.

Shares of Natural Alternatives (NAII) jumped 17% after the nutritional supplements company posted a big jump in third-quarter earnings. The company earned $621,000, or 9 cents a share, up from $277,000, or 4 cents a share, a year earlier. Revenue rose to $23.3 million from $22.5 million. The results were helped by the company's recent acquisition of Real Health Laboratories, which added $2.7 million in sales.

Looking ahead, Natural Alternatives sees fourth-quarter revenue of $33 million. During the year-earlier period, the company recorded revenue of $24.7 million. Shares recently advanced $1.41 to $9.86.

Par Pharmaceutical (PRX) shares rose modestly after the company posted in-line first-quarter earnings on better-than-expected revenue. The company earned $8.4 million, or 24 cents a share, on revenue of $173.8 million. Analysts expected earnings of 24 cents a share and a top line of $145.7 million. During the year-earlier period, the company recorded earnings from continuing operations of $2.7 million, or 8 cents a share, on revenue of $97.5 million. "Par significantly improved its financial performance despite the continued investment necessary to build its branded pharmaceutical organization and its first brand," the company said. Shares were trading up 16 cents to $25.91.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs